<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_NTU-Taida_Project_Effector"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:NTU-Taida/Project/Effector">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:NTU-Taida/Project/Effector&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:NTU-Taida/Project/Effector&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:NTU-Taida/Project/Effector&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:NTU-Taida/Project/Effector" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:NTU-Taida/Project/Effector</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2012.igem.org</H3><DIV class="navbar navbar-fixed-top"><DIV class="navbar-inner"><DIV class="container"><A class="brand" href="/Team:NTU-Taida">NTU-Taida</A><DIV class="nav-collapse"><UL class="nav" id="wiki-navbar"><LI id="nav-Home"><A href="/Team:NTU-Taida">Home</A></LI><LI class="dropdown" id="nav-Project"><A class="dropdown-toggle" data-toggle="dropdown" href="#">Project</A></LI><LI id="nav-Project-Intro"><A href="/Team:NTU-Taida/Project/Introduction">Introduction</A></LI><LI id="nav-Project-Background"><A href="/Team:NTU-Taida/Project/Background">Background</A></LI><LI id="nav-Project-Overview"><A href="/Team:NTU-Taida/Project/Overview">Project Overview</A></LI><LI id="nav-Project-Effector" style="margin-left: 10px;"><A href="/Team:NTU-Taida/Project/Effector">Effector</A></LI><LI id="nav-Project-Sensor" style="margin-left: 10px;"><A href="/Team:NTU-Taida/Project/Sensor">Sensor</A></LI><LI id="nav-Project-Circuit" style="margin-left: 10px;"><A href="/Team:NTU-Taida/Project/Circuit">Circuit</A></LI><LI id="nav-Project-Stability" style="margin-left: 10px;"><A href="/Team:NTU-Taida/Project/Stability">Stability</A></LI><LI id="nav-Project-Safety" style="margin-left: 10px;"><A href="/Team:NTU-Taida/Project/Safety">Safety</A></LI><LI id="nav-Project-Future"><A href="/Team:NTU-Taida/Project/Future-Plan">Future Plan</A></LI></UL><LI class="dropdown" id="nav-Result"><A class="dropdown-toggle" data-toggle="dropdown" href="#">Result</A></LI><LI id="nav-Result-pFadBA"><A href="/Team:NTU-Taida/Result/pFadBA">pFadBA Promoter</A></LI><LI id="nav-Result-Thermal"><A href="/Team:NTU-Taida/Result/Thermal-Promoter">Thermal Promoter</A></LI><LI id="nav-Result-clPromoter"><A href="/Team:NTU-Taida/Result/Modified-cI-promoter">Modified cI promoter</A></LI><LI id="nav-Result-Secetion-CPP"><A href="/Team:NTU-Taida/Result/Secretion-CPP">Secretion: CPP</A></LI><LI id="nav-Result-Secetion-GLP1"><A href="/Team:NTU-Taida/Result/Secretion-GLP1">Secretion: GLP-1</A></LI><LI id="nav-Result-Penetration"><A href="/Team:NTU-Taida/Result/Penetration">Penetration</A></LI><LI id="nav-Result-Stability"><A href="/Team:NTU-Taida/Result/Stability">Stability</A></LI><LI class="dropdown" id="nav-Modeling"><A class="dropdown-toggle" id="nav-model-overview" data-toggle="dropdown" href="#">Modeling</A></LI><LI id="nav-Modeling-Overview"><A href="/Team:NTU-Taida/Modeling">Overview</A></LI><LI id="nav-Modeling-Single"><A href="/Team:NTU-Taida/Modeling/Single-Cell">Single Cell Model</A></LI><LI id="nav-Modeling-FA"><A href="/Team:NTU-Taida/Modeling/FA">Fatty Acid Reaction-Absorption Model</A></LI><LI id="nav-Modeling-System"><A href="/Team:NTU-Taida/Modeling/System-Analysis">System Analysis</A></LI><LI id="nav-Modeling-Stochastic"><A href="/Team:NTU-Taida/Modeling/Stochastic-Analysis">Stochastic Analysis</A></LI><LI id="nav-Modeling-Combined"><A href="/Team:NTU-Taida/Modeling/2D-3D-Combined">2D &amp; 3D Combined Model</A></LI><LI id="nav-Modeling-Plasmid"><A href="/Team:NTU-Taida/Modeling/Plasmid-Stability">Plasmid Stability Model</A></LI><LI id="nav-Modeling-Parameters"><A href="/Team:NTU-Taida/Modeling/Parameters">Parameters</A></LI><LI id="nav-Parts"><A href="/Team:NTU-Taida/Parts">Parts</A></LI><LI id="nav-Safety"><A href="/Team:NTU-Taida/Safety">Safety</A></LI><LI id="nav-Team"><A href="/Team:NTU-Taida/Team">Team</A></LI><LI class="dropdown" id="nav-HumanPractice"><A class="dropdown-toggle" data-toggle="dropdown" href="#">Human Practice</A></LI><LI id="nav-HumanPractice-Overview"><A href="/Team:NTU-Taida/Human Practice/Overview">Overview</A></LI><LI id="nav-HumanPractice-DesignThinking"><A href="/Team:NTU-Taida/Human Practice/Design">Design Thinking in Synthetic Biology</A></LI><LI id="nav-HumanPractice-Symposium"><A href="/Team:NTU-Taida/Human Practice/Symposium">Symposium with High School Students</A></LI><LI id="nav-HumanPractice-Questionnaire"><A href="/Team:NTU-Taida/Human Practice/Questionnaire">Questionnaire Analysis</A></LI><LI id="nav-HumanPractice-SafetyiniGEM"><A href="/Team:NTU-Taida/Human Practice/Safety-in-iGEM">Safety in iGEM</A></LI><LI id="nav-HumanPractice-DoctorInterview"><A href="/Team:NTU-Taida/Human Practice/Doctor-Interview">Doctor Interview</A></LI><LI id="nav-HumanPractice-Collaboration"><A href="/Team:NTU-Taida/Human Practice/Collaboration">Collaboration and Other Activities</A></LI><LI id="nav-HumanPractice-InformationPlatform"><A href="/Team:NTU-Taida/Human Practice/Information-Platform">Information Platform</A></LI><LI class="dropdown" id="nav-user"><A class="dropdown-toggle" id="nav-login" role="button" data-toggle="dropdown" data-target="#" href="">
              Login
            </A></LI><LI><A href="" id="nav-edit">Edit</A></LI><LI><A href="" id="nav-history">History</A></LI><LI><A href="/Special:Upload" id="nav-upload">Upload</A></LI><LI><A href="" id="nav-logout">Logout</A></LI></DIV></DIV></DIV></DIV><DIV class="container"><DIV class="row" id="maintext"><DIV class="span3 my-sidebar"><DIV class="my-sidebar-nav"><H4 class="lead">Effector</H4></DIV></DIV><DIV class="span9"><DIV class="hero-unit" style="margin-top: 20px; margin-bottom: 0px;"><H1>Effector</H1><P>We use neuropeptide GLP-1 as the effector. Targeting to the brain, it can modulate the eating behavior of hosts and has neuroprotective function as well. Cell penetrating peptide and signal sequence are designed for facilitation of penetration and secretion, respectively.</P></DIV><TABLE id="toc" class="toc"><TBODY><TR><TD><DIV id="toctitle"><H2>Contents</H2></DIV><UL><LI class="toclevel-1 tocsection-1"><A href="#Glucagon-like_Peptide-1"><SPAN class="tocnumber">1</SPAN><SPAN class="toctext">Glucagon-like Peptide-1</SPAN></A></LI><LI class="toclevel-2 tocsection-2"><A href="#Fat_Extinguisher.E2.80.94Reduction_in_Eating_Behavior"><SPAN class="tocnumber">1.1</SPAN><SPAN class="toctext">Fat Extinguisher—Reduction in Eating Behavior</SPAN></A></LI><LI class="toclevel-2 tocsection-3"><A href="#Brain_Guardian.E2.80.94Memory_Improvement_and_Neuroprotection"><SPAN class="tocnumber">1.2</SPAN><SPAN class="toctext">Brain Guardian—Memory Improvement and Neuroprotection</SPAN></A></LI></UL><LI class="toclevel-1 tocsection-4"><A href="#Cell_Penetrating_Peptide"><SPAN class="tocnumber">2</SPAN><SPAN class="toctext">Cell Penetrating Peptide</SPAN></A></LI><LI class="toclevel-1 tocsection-5"><A href="#Secretion"><SPAN class="tocnumber">3</SPAN><SPAN class="toctext">Secretion</SPAN></A></LI><LI class="toclevel-2 tocsection-6"><A href="#Type_2_Secretion_System"><SPAN class="tocnumber">3.1</SPAN><SPAN class="toctext">Type 2 Secretion System</SPAN></A></LI><LI class="toclevel-2 tocsection-7"><A href="#Signal_Peptides"><SPAN class="tocnumber">3.2</SPAN><SPAN class="toctext">Signal Peptides</SPAN></A></LI><LI class="toclevel-1 tocsection-8"><A href="#Reference"><SPAN class="tocnumber">4</SPAN><SPAN class="toctext">Reference</SPAN></A></LI></TD></TR></TBODY></TABLE><H2><SPAN class="mw-headline" id="Glucagon-like_Peptide-1">Glucagon-like Peptide-1</SPAN></H2><P style="text-indent: 2em;"><B>Glucagon-like Peptide-1 (GLP-1)</B> is one of the members of <B>incretin</B>, a group of gastrointestinal hormones secreted by endocrine cells in small intestine that mainly work to increase insulin levels. Under normal physiological condition, this 30-amino acid peptide is secreted by L cells, a kind of neuroendocrine cell located in small intestine after a meal, into the circulation, promoting insulin release and inhibit energy intake. Its natural form can be degraded by DPP-4, having a half life of 1-2 minutes. GLP-1 mainly acts on the <B>GLP-1 receptor</B>, a G-protein coupled receptors, coupled with adenylyl cyclase downstream and signaling on PI3K/Akt and ERK1/2 pathways via second messenger cAMP. It promotes the secretion of insulin in β cells of islets in pancreas, antagonizes and glucose-rising effect of glucagon, and largely increase the insulin sensitivity of targeted cells. GLP-1 analogues such as Liraglutide and Exentide   and DPP-4 inhibitors have been used clinically as treatment for patients with <B>type 2 diabetes mellitus (T2DM)</B>, but recently, more and more focus has been spotted on its versatile functions, such as cardiovascular regulation, appetite inhibition, and neuroprotective effects. Here we aim to utilize the functions in appetite inhibition and neuroprotection of GLP-1, in order to tailor our PEPDEX as a living machine that communicate with our central nervous systems and modulate our eating behavior, as well as improve our cognitive function to prevent neurodegenerative diseases.</P><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:502px;"><DIV class="thumbcaption">Versatile function of GLP-1</DIV></DIV></DIV></DIV><H3><SPAN class="mw-headline" id="Fat_Extinguisher.E2.80.94Reduction_in_Eating_Behavior">Fat Extinguisher—Reduction in Eating Behavior</SPAN></H3><P>Obesity and metabolic syndrome have been regarded as chronic disease recent decades. It is reported that people with obesity or metabolic syndromes are in a higher risk of type II diabetes, cardiovascular disease and hypertension. Nowadays, there are 1 billion people encountering over-weight problem, and 30 million people are diagnosed of obesity. Modern dietary pattern has been considered the major cause contributing to the phenomena. 
GLP-1 is known to act on the <B>satiety center</B> inside <B>hypothalamic regions</B> of brains, inhibiting <B>appetite</B> and modulating <B>feeding behavior</B>. Therapeutic use of anti-obesity has also been proved by different drug authorities. In PepdEx, we put GLP-1 production under the control of a circuit with a fatty acid sensor, mimicking the physiological response that GLP-1 is released after food intake. Induced by a fat meal, bacterial secreted GLP-1 are expected to penetrate the intestinal epithelium with the assistance of cell penetrating peptide <B>Penetratin</B>, circulating to the brain and perform its behavior-regulating function.
</P><H3><SPAN class="mw-headline" id="Brain_Guardian.E2.80.94Memory_Improvement_and_Neuroprotection">Brain Guardian—Memory Improvement and Neuroprotection </SPAN></H3><P>Besides regulation of appetite, GLP-1 also has wide effects on the central nervous system, including promotion of learning and memory and neuroprotective roles. GLP-1 receptors are distributed among the brain in various regions such as <B>hypothalamus</B>, <B>thalamus</B>, <B>brainstem</B>, and <B>hippocampus</B>. Studies using in vitro culture and animal models indicate that GLP-1 promote the learning and memory function in CA1 region of hippocampus, via increase of <B>long-term potentiation (LTP)</B> and enhancement of <B>synaptic plasticity</B>. It also reduces the destructive effects of Aβ amyloid and preserve and dopaminergic neurons in <B>Alzheimer’s disease</B> and <B>Parkinson’s disease</B>, respectively. Potentiation of neuronal differentiation, promotion of cell survival, up-regulation of neurotransmitter synthesis and modulation of glial cells are other functions of GLP-1 in CNS that have been reported, while more diseases such as <B>Huntington’s disease</B>, <B>stroke</B>, and <B>peripheral sensory neuropathy</B> potentially become its therapeutic targets. Conjugation with a thermal regulatory promoter gives a constitutive delivery of GLP-1 inside the human body, which constantly stimulates and protects the CNS, in improvement of learning and memory and prevention of neurodegenerative diseases.
</P><OL><LI>De Silva A, et al. (2011) The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans. Cell Metab <B>14(5)</B>:700-6.</LI><LI>Owais B, et al. (2005) The gastrointestinal tract and the regulation of appetite. Drug Discovery Today: Disease Mechanisms <B>2(3)</B>:289-94.</LI><LI>MacDonald PE, et al. (2002) The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion. Diabetes <B>51 Suppl 3</B>:S434-42</LI><LI>Choi S, et al. (2005) Glucagon-like Peptide-1 Plasmid Construction and Delivery for the Treatment of Type 2 Diabetes. Mol Ther <B>12(5)</B>:885-91.</LI><LI>Baggio LL, et al. (2007) Biology of Incretins: GLP-1 and GIP. Gastroenterology <B>132(6)</B>:2131-57.</LI><LI>P Puska, et al. Obesity and Overweight. World Health Organization</LI><LI>Di Marino L, et al. (2011) Active glucagon-like peptide-1 (GLP-1): Storage of human plasma and stability over time. ClinicaChimicaActa <B>412(17-18)</B>:1693-94.</LI><LI>Degn KB, et al. (2004) One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes <B>53(5)</B>:1187-94.</LI><LI>Ranganath LR, et al. (1996) Attenuated GLP-1 secretion in obesity: cause or consequence? Gut <B>38(6)</B>:916-9.</LI><LI>Li Y, et al. (2010) GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis <B>19(4)</B>: 1205–1219.</LI><LI>Biswas SC, et al. (2008) Glucagon-like Peptide-1 (GLP-1) Diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem Res <B>33</B>:1845–1851.</LI><LI>Lin L. (2008) Commonality between diabetes and Alzheimer’s disease and a new strategy for the therapy. Clinical Medicine: Pathology <B>1</B>: 83–91.</LI><LI>Li Y, et al. (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Nat Acad Sci <B>106(4)</B>: 1285-1290.</LI><LI>Mossello E, et al. (2011) Glucagon-like peptide-1, diabetes, and cognitive decline: Possible pathophysiological links and therapeutic opportunities. Experimental Diabetes Research <B>2011</B>:1-6.</LI><LI>Abbas T, et al. (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer’s disease. Behavioural Brain Research <B>205</B>:265–271.</LI><LI>Holst JJ, et al. (2011) Neuroprotective properties of GLP-1: theoretical and practical applications. Current Medical Research &amp; Opinion <B>27(3)</B>:547–558.</LI><LI>Bak AM, et al. (2011) Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer’s disease and diabetes. Expert Opin. Ther. Targets <B>15(10)</B>:1153-1162.</LI><LI>McClean PL, et al. (2011) The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. The Journal of Neuroscience <B>31(17)</B>:6587–6594.</LI><LI>Pratley RE. (2008) The new science of GLP-1: Effects beyond glucose control. Adv Stud Med. <B>8(11)</B>:393-399.</LI></OL><H2><SPAN class="mw-headline" id="Cell_Penetrating_Peptide">Cell Penetrating Peptide </SPAN></H2><P>One obstacle needs to be overcome is the poor penetrating ability of GLP-1 through the intestinal epithelia, since GLP-1 is neither small molecule nor hydrophobic. However, several studies have shown that some short peptides known as <B>cell penetrating peptides (CPPs)</B> can help to deliver biodrugs through intestinal mucosa and increase their bioavailability. CPPs are usually arginine-rich, tend to interact with extracellular matrix and can enhance macropinocytosis of epithelial cells. One recent study even demonstrated that co-administration of GLP-1 and <B>Penetratin</B>, one of the CPPs, greatly increased the intestinal absorption rate to 5%.  By applying cell penetrating peptide to our device, we aim to promote the delivery of GLP-1 from intestinal lumen to blood stream, therefore enhance their appetite-regulating effect.
</P><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:502px;"><DIV class="thumbcaption">Transepithelial effect of CPP</DIV></DIV></DIV></DIV><P><TABLE class="table table-bordered table-hover"><TBODY><TR><TD><B>Peptides</B></TD><TD><B>Sequence</B></TD></TR><TR><TD><I>Arginine rich peptides</I></TD></TR><TR><TD>Arginine octamer (R8)</TD><TD>RRRRRRRR</TD></TR><TR><TD>Arginine dodecamer (R12)</TD><TD>RRRRRRRRRRRR</TD></TR><TR><TD>HIV-1 Tat (48–60)</TD><TD>GRKKRRQRRRPPQ</TD></TR><TR><TD>HIV-1 Rev (34–50)</TD><TD>TRQARRNRRRRWRERQR</TD></TR><TR><TD><I>Amphipathic peptides</I></TD></TR><TR><TD><B>Penetratin</B></TD><TD><B>RQIKIWFQNRRMKWKK</B></TD></TR><TR><TD>pVEC</TD><TD>LLIILRRRIRKQAHAHSK</TD></TR><TR><TD>Erns</TD><TD>RQGAARVTSWLGLQLRIGK</TD></TR><TR><TD>RRL helix</TD><TD>RRLRRLLRRLRRLLRRLR</TD></TR><TR><TD>PRL4</TD><TD>PRLPRLPRLPRL</TD></TR><TR><TD><I>Random composition peptides</I></TD></TR><TR><TD>Random peptide</TD><TD>GLSASPNLQFRTV</TD></TR></TBODY></TABLE></P><OL><LI>Khafagy el-S, et al. (2012) Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev <B>64(6)</B>:531-9.</LI><LI>Khafagy el-S, et al. (2009) Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int J Pharm <B>381(1)</B>:49-55.</LI><LI>Nakase I, et al. (2004) Cellular Uptake of Arginine-Rich Peptides: Roles for Macropinocytosis and Actin Rearrangement. Mol Ther <B>10(6)</B>:1011-22.</LI></OL><H2><SPAN class="mw-headline" id="Secretion">Secretion</SPAN></H2><P>In order to achieve the extracellular secretion of our recombinant peptide GLP-1 and CPP, we utilize the endogenous type 2 secretion system (T2SS) in bacteria with specific signal peptides added to the N-terminus of GLP-1 and CPP.
</P><H3><SPAN class="mw-headline" id="Type_2_Secretion_System">Type 2 Secretion System</SPAN></H3><P>Secretion systems of gram-negative bacteria are categorized into 6 types, from type 1 secretion system (T1SS) to type 6 secretion system (T6SS). Among these secretion systems, type 1 and type 2 secretion systems are in charge of transport bacterial protein products into the extracellular space. <A href="#Ref"> [1] </A> Here we choose type 2 secretion system (T2SS) as our secretion apparatus which is widely found in gram-negative bacteria, including E. coli. Unlike the single-step secretion of T1SS such as hemolysin transport system (Hly), T2SS has two-step secretion processes. Unfolded or folded proteins with specific signal sequences on their N-terminus are first transported through the inner membrane into the periplasmic space via Sec translocon or twin-arginine translocation (Tat) pathway, respectively. <A href="#Ref"> [1, 4, 5] </A> The cleavage of signal peptides is performed by signal peptidase inside the periplasm. Proteins of proper structural features are then transported through the outer membrane into the extracellular space via general secretory pathway (GSP) which consists of 4 distinguished subassemblies: inner membrane platform, outer membrane complex, pseudopilus, and secretion ATPase (Fig. 1) <A href="#Ref"> [2, 3] </A>, while small proteins (in our case, short peptides) can also leak from the periplasmic into the environment, regarding the integrity of the outer membrane. Co-expressions of some genes, such as kil, out, tolAIII, and bacteriocin release protein (BRP), were reported to facilitate the extracellular secretory processes. <A href="#Ref"> [1] </A></P><DIV class="center"><DIV class="thumb tnone"><DIV class="thumbinner" style="width:602px;"><DIV class="thumbcaption">Summary of Type 2 Secretion System</DIV></DIV></DIV></DIV><H3><SPAN class="mw-headline" id="Signal_Peptides">Signal Peptides</SPAN></H3><P>The selection of signal sequence for delivery of specific recombinant proteins is mostly based on empirical data. Some representative signal sequences, such as those of PhoA (alkaline phosphatase), PelB (pectate lysase B), OmpA (outer-membrane protein A), OmpF (outer-membrane protein F), StII (heat-stable enterotoxin 2), or LTB (heat-labile enterotoxin subunit B), are commonly used. We survey papers of successfully secretion of recombinant proteins with specific signal sequences, and choose 3 sequences which were reported to work in the bacterial strains (E. coli DH5α and BL21) we use. They are signal sequences of PhoA <A href="#Ref"> [6] </A>, LTB <A href="#Ref"> [7] </A>, and StII <A href="#Ref"> [8] </A>, named signal peptide 1 (SP1), signal peptide 2 (SP2), and signal peptide 3 (SP3), respectively. Targeting to the Sec pathway, these signal sequences are cleaved in the periplasmic space, which helps to preserve the structural and functional integrity of the original the peptide. This is also an advantage to choose the T2SS as our delivery system.
</P><P><TABLE class="table table-bordered"><THEAD><TR><TH>Signal Peptide</TH><TH>Source</TH><TH>Sequence</TH></TR></THEAD><TBODY><TR><TD>SP1</TD><TD>PhoA</TD><TD>MKQSTIALALLPLLFTPVTKA</TD></TR><TR><TD>SP2</TD><TD>LTB</TD><TD>MNKVKCYVLFTALLSSLYAHG</TD></TR><TR><TD>SP3</TD><TD>StII</TD><TD>MKKNIAFLLASMFVFSIATNAYA</TD></TR></TBODY></TABLE></P><H2><SPAN class="mw-headline" id="Reference">Reference</SPAN></H2><OL id="Ref"><LI>Choi JH, et al. (2004) Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol <B>64</B>: 625-635.</LI><LI>Korotkov KV, et al. (2012) The type II secretion system: biogenesis, molecular architecture and mechanism. Nat Rev Microbiol <B>10(5)</B>:336-51.</LI><LI>Filloux A (2004) The underlying mechanisms of type II protein secretion. Biochim Biophys Acta <B>1694(1-3)</B>:163-79.</LI><LI>Muller M, et al. (2005) The Tat pathway in bacteria and chloroplasts. Molecular Membrane Biology <B>22(1-2)</B>: 113-121.</LI><LI>5DeLisa MP, et al. (2003) Folding quality control in the export of proteins by the bacterial twin-arginine translocation pathway. Proc Natl Acad Sci <B>100(10)</B>:6115-20.</LI><LI>Xu R, et al. (2002) High-level expression and secretion of recombinant mouse endostatin by Escherichia coli. Protein Expr Purif <B>24</B>:453-459.</LI><LI>Pillai D, et al. (1996) Production of the beta-subunit of human chorionic gonadotropin in Escherichia coli and its export mediated by the heat-labile enterotoxin chain-B signal sequence. Gene <B>173(2)</B>:271-274.</LI><LI>Dracheva S, et al. (1995) Expression of soluble human interleukin-2 receptor α-chain in Escherichia coli. Protein Expr Purif <B>6</B>:737-747.</LI><LI>Mitra K, et al. (2005) Structure of E. coli protein-conducting channel bound to a translating ribosome. Nature <B>438</B>:318-24.</LI><LI>Dekker C, et al. (2003) Crystal structure of SecB from Escherichia coli. Journal of Structural Biology <B>144</B>:313-319.</LI><LI>Mergulhao FJM, et al. (2005) Recombinant protein secretion in Escherichia coli. Biotechnology Advances 23:177-202.</LI><LI>Papanikolau Y, et al. (2006) Structure of Dimeric SecA, the Escherichia coli Preprotein Translocase Motor. J Mol Biol 366:1545-1557.</LI><LI>Steiner D, et al. (2006) Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display. Nature Biotechnology 24:823-31.</LI></OL></DIV></DIV></DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2012.igem.org/Team:NTU-Taida/Project/Effector">http://2012.igem.org/Team:NTU-Taida/Project/Effector</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:NTU-Taida/Project/Effector" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:NTU-Taida/Project/Effector" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:NTU-Taida/Project/Effector&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:NTU-Taida/Project/Effector&amp;oldid=294621" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2012.igem.org:Privacy_policy" title="2012.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2012.igem.org:General_disclaimer" title="2012.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>